Enlarge image
Corona fighters:
The vaccine from Biontech and Pfizer (Biontech boss
Ugur Şahin
in the picture
) was the first vaccine worldwide to be approved at the end of 2020
Photo: Florian Gaertner / imago images / photothek
The success of its corona vaccine has brought the Mainz company Biontech a huge leap in sales and profits.
As the company announced on Monday, net profit rose to just under 2.8 billion euros in the second quarter of 2021 after a loss of 88.3 million euros in the same period of the previous year.
For the first six months of this year, the surplus amounted to a good 3.9 billion euros after a loss of almost 142 million euros in the previous year.
Sales in the quarter ended June 30th were estimated at around 5.3 billion euros after 41.7 million euros in the previous year.
For the first half of the year there was a total turnover of almost 7.4 billion euros after 69 million euros in the same period of the previous year.
The management of company
founder Ugur Şahin
(55)
raised the sales forecast for the current year
to 15.9 (previously: 12.4) billion euros.
The sales expectation is based on the currently signed supply contracts for around 2.2 billion vaccine doses in 2021, as the company further announced.
US partner Pfizer had raised the sales forecast for the vaccine at the end of July after further supply contracts were concluded.
Overall, Biontech is now aiming for a production capacity of three billion cans by the end of the year and a further four billion units in 2022.
Biontech is now worth around $ 100 billion
The company's success is also reflected in the stock market. The paper, which has been listed on the US technology exchange Nasdaq since October 2019, has rushed from record to record in the past few weeks. On Tuesday, the price rose to $ 433.90 - Biontech was at times worth more than $ 100 billion. By Friday the course crumbled again a little. At 389 dollars, however, it was still around 1200 percent above the level at the end of January 2020, before the corona pandemic hit the world. Most recently, the stock was quoted just under 6 percent higher at $ 410.
Since the IPO in autumn 2019, the price has increased by around 2500 percent.
Biontech is currently worth around 94 billion dollars or the equivalent of almost 80 billion euros on the stock exchange.
Due to the rapid rise in the share price, the twin brothers
Andreas and Thomas Strüngmann
(71), who hold almost half of the shares, are now among the richest Germans.
The 17 percent package from company boss Şahin is worth almost 14 billion euros.
mg / dpa-afx, Reuters
